Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

Leukemia can broadly be categorized as being acute or chronic. Each can manifest with different symptoms and at different rates. Acute leukemia is caused when blood stem cells fail to mature into ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take place in the blood system over the ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...